Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome

Journal of Research in Medical Sciences

Volumn 19, Issue 5, 2014, Pages 404-409

  Ruan, Zhong Bao ^a   Zhu, Li ^a   Yin, Yi Gang ^a   Chen, Ge Cai ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

Author keywords

Acute heart failure; Acute kidney injury; Cardiorenal syndrome; Cystatin C; N terminal probrain natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD PRESSURE; CARDIORENAL SYNDROME; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; TURBIDIMETRY; UREA NITROGEN BLOOD LEVEL;

EID: 84903130588     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ben-Shoshan J, Entin-Meer M, Guzner-Gur H, Keren G. The cardiorenal syndrome: A mutual approach to concomitant cardiac and renal failure. Isr Med Assoc J 2012;14:570-6.
2. Eren Z, Ozveren O, Buvukoner E, Kaspar E, Degertekin M, Kantarci G. A Single-Centre Study of Acute Cardiorenal Syndrome: Incidence, Risk Factors and Consequences. Cardiorenal Med 2012;2:168-76.
3. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39.
4. Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirilä-Waris K, Sund R, et al. Markers of renal function and acute kidney injury in acute heart failure: Definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010;31:2791-8.
5. Lassus J, Harjola VP. Cystatin C: A step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2012;17:251-61.
6. Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen K, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007;28:1841-7.
7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
8. Aslam M, Asif M, Altaf S. Estimation of smoking index for male smokers in Multan City. Pak J Nutr 2011;10:80-5.
9. Yang Lin, Mei Chen, Chun-fang Wu, Piao Huang. Cystatin C and alpha-L-fucosidase in diabetic nephropathy. Lab Med Clin 2013;10:575-6.
10. Bai L, Chen ZN, Liao SW, Liang Q. Application of NT-proBNP levels in the diagnosis of emergency breathing difficulties. China Mod Doct 2012;50:24-6.
11. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
12. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11.
13. Coats CJ, Parisi V, Ramos M, Janagarajan K, O'Mahony C, Dawnay A, et al. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol 2013;111: 111-7.
14. Kshatriya S, Kozman H, Siddiqui D, Bhatta L, Liu K, Salah A, et al. The cardiorenal syndrome in heart failure: An evolving paradigm. Am J Med Sci 2010;340:33-7.
15. Ahmed MS, Wong CF, Pai P. Cardiorenal syndrome-a new classification and current evidence on its management. Clin Nephrol 2010;74:245-57.
16. Jensen J, Ma LP, Bjurman C, Hammarsten O, Fu ML. Prognostic values of NTpro BNP/BNP ratio in comparison with NTpro BNP or BNP alone in elderly patients with chronic heart failure in a 2-year follow up. Int J Cardiol 2012;155:1-5.
17. Nosaka K, Nakamura K, Kusano K, Toh N, Tada T, Miyoshi T, et al. Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction. Congest Heart Fail 2013;19:E35-9.
18. Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008;31:971-3.
19. Mahadevan G, Dwivedi G, Williams L, Steeds RP, Frenneaux M. Epidemiology and diagnosis of heart failure with preserved left ventricular ejection fraction: Rationale and design of the study. Eur J Heart Fail 2012;14:106-12.
20. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 2008;14:394-9.
21. Alehagen U, Dahlström U, Lindahl TL. Cystatin C and NTproBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: Results from a 10-year study in primary care. Eur J Heart Fail 2009;11:354-60.
22. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8.
23. Smilde TD, Hillege HL, Navis G, Boomsma F, de Zeeuw D, van Veldhuisen DJ. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: Association with neurohormonal activation and survival. Am Heart J 2004;148:165-72.